We are live on ! Find out more
EW icon

Edwards Lifesciences

816 hedge funds and large institutions have $24.3B invested in Edwards Lifesciences in 2018 Q1 according to their latest regulatory filings, with 118 funds opening new positions, 237 increasing their positions, 311 reducing their positions, and 68 closing their positions.

New
Increased
Maintained
Reduced
Closed

74% more first-time investments, than exits

New positions opened: 118 | Existing positions closed: 68

62% more funds holding in top 10

Funds holding in top 10: 1321 (+8)

24% more capital invested

Capital invested by funds: $19.6B → $24.3B (+$4.79B)

24% more call options, than puts

Call options by funds: $112M | Put options by funds: $90.4M

6% more funds holding

Funds holding: 773816 (+43)

2.95% more ownership

Funds ownership: 246.48%249.42% (+2.9%)

24% less repeat investments, than reductions

Existing positions increased: 237 | Existing positions reduced: 311

Holders
816
Holders Change
+43
Holders Change %
+5.56%
% of All Funds
18.7%
Holding in Top 10
21
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+61.54%
% of All Funds
0.48%
New
118
Increased
237
Reduced
311
Closed
68
Calls
$112M
Puts
$90.4M
Net Calls
+$22M
Net Calls Change
+$22M
Name Holding Trade Value Shares
Change
Change in
Stake
CWM
251
CIBC World Markets
New York
$5.43M -$1.07M -24,597 -17%
FA
252
Friess Associates
Delaware
$5.42M +$5.06M +116,550 New
Public Employees Retirement Association of Colorado
253
Public Employees Retirement Association of Colorado
Colorado
$5.38M -$224K -5,148 -4%
NMIMC
254
Northwestern Mutual Investment Management Company
Wisconsin
$5.33M -$1.25M -28,710 -20%
FMII
255
Farmers & Merchants Investments Inc
Nebraska
$5.31M -$85.6K -1,971 -2%
N
256
Natixis
France
$5.22M +$2.83M +65,199 +138%
BAMCO Inc
257
BAMCO Inc
New York
$5.18M -$16.8K -387 -0.3%
MLIC
258
Mandatum Life Insurance Company
Finland
$5.13M
MME
259
Meag Munich Ergo
Germany
$5.09M +$3.55M +81,783 +270%
MOACM
260
Mutual of America Capital Management
New York
$5.08M -$65K -1,497 -1%
BNP Paribas Financial Markets
261
BNP Paribas Financial Markets
France
$5.08M -$2.25M -51,825 -32%
CS
262
Candriam SCA
Luxembourg
$5.04M +$641K +14,763 +16%
MSL
263
Mackay Shields LLC
New York
$4.97M +$4.64M +106,866 New
CG
264
Colony Group
Massachusetts
$4.95M +$4.62M +106,329 New
M&T Bank
265
M&T Bank
New York
$4.94M -$293K -6,744 -6%
SDIC
266
South Dakota Investment Council
South Dakota
$4.9M -$808K -18,600 -15%
Financial Engines Advisors
267
Financial Engines Advisors
California
$4.81M -$1.67M -38,484 -27%
SC
268
Scholtz & Company
Connecticut
$4.79M -$45.6K -1,050 -1%
BFIM
269
Beese Fulmer Investment Management
Ohio
$4.76M +$341K +7,863 +8%
BF
270
BOK Financial
Oklahoma
$4.76M +$3.43M +79,035 +340%
SAM
271
Shell Asset Management
Netherlands
$4.74M +$32.6K +750 +0.7%
Creative Planning
272
Creative Planning
Kansas
$4.72M +$65.4K +1,506 +2%
MSV
273
MN Services Vermogensbeheer
Netherlands
$4.65M +$91.2K +2,100 +2%
RB
274
Rodgers Brothers
Pennsylvania
$4.57M -$199K -4,575 -4%
EIM
275
ExxonMobil Investment Management
Texas
$4.49M -$195K -4,488 -4%

EW Hedge Fund Activity: Q1 2018 in Review

816 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q1 2018, worth a combined $24.3B — up 24% from $19.6B a quarter earlier.

Buyers outnumbered sellers: 118 funds opened new EW positions and 68 closed out — a net gain of 50 holders — while 237 added to existing stakes and 311 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $553M. The largest seller was AllianceBernstein, cutting an estimated $170M.

  • 816 institutional investors held Edwards Lifesciences (EW) as of Q1 2018, up from 773 in Q4 2017.
  • Funds reported $24.3B of Edwards Lifesciences stock for Q1 2018, up 24% quarter-over-quarter.
  • 118 funds opened new Edwards Lifesciences positions in Q1 2018 and 68 closed out, a net change of +50 holders.
  • The largest Edwards Lifesciences buyer in Q1 2018 was Fidelity Investments, an estimated $553M added.
  • The largest Edwards Lifesciences seller in Q1 2018 was AllianceBernstein, an estimated $170M sold.

Based on aggregated 13F filings for Q1 2018.